Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
about
Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trialsSuccessful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutantHepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcomeOutcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listResistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxilManagement of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Current antiviral therapy for chronic hepatitis B.Application of hepatitis B virus replication mouse modelPegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.Too much of a good thing? When to stop catch-up vaccinationSystematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysisResponse-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective studyYMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation.Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysisVirological response to adefovir monotherapy and the risk of adefovir resistanceEmerging drugs for hepatitis B.Recent advances in the management of chronic hepatitis B.Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategiesIn vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patientsLamivudine for chronic hepatitis B.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Current therapies for chronic hepatitis B virus infection.Adefovir dipivoxil in chronic hepatitis B infection.Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.Management of chronic hepatitis B virus infection: a new era of disease control.Personal view: the management of chronic hepatitis B infection.Review article: hepatitis B and liver transplantation.
P2860
Q24683341-F2539465-FBB0-4CB3-A858-38FCEA97A151Q25256648-E81605F2-7889-4552-8F52-7E64A9130149Q26859121-A2B37556-C58D-47ED-BD8B-03F7A8E92119Q30440211-810F9838-84A5-463C-B94B-547ECD6FC2C8Q33233245-A2AF9CCD-368B-4675-9111-ADF7993A7F68Q33242705-133E7982-14B3-403A-8894-4FD27A44693BQ33492413-D0C3026C-06B5-4D4A-BD7C-B8219A704DE4Q33631693-FFDCCD05-2108-4F90-9C9F-2B634045D9D2Q33812160-33644515-64A7-435B-8B72-8FD0A494D248Q33868880-5D3999AB-3D47-4AFF-BADB-93FBE0E2969CQ33905600-A4EBB3E2-5659-4427-9F1F-D193D16F10FDQ34339608-8792CBA7-E994-4534-9C26-903AE4190D34Q34382067-0346104B-8AE7-46A4-9FB5-64B6F33F135EQ34464655-4B2647EC-E443-45EE-8758-C56FE0B29CEEQ34584406-176BF38C-EE4F-4181-961F-D66A94371CACQ34585496-61228315-DCB6-4758-9C84-1AA369D85EF8Q34594403-624022BC-7F3B-4088-8F06-95ACA0EA8FD6Q34604733-C03A8195-BAAD-408B-A99C-7A9A9D20EAB5Q34615975-8494B180-49D2-4DE0-803A-63223A944787Q34974141-48EF7C04-F625-402B-8A9E-6A2C6FE26678Q35011213-D6556701-9A9F-4DDE-843D-EB48A2729F82Q35152367-1606927E-F3D0-4DB0-9F8C-63C463BBE983Q35180009-484E870B-4E40-47AB-8DA8-24BF97742F2CQ35185125-5CE90738-C74B-4D6C-BA71-8864CB59674FQ35359369-E0ECD7A5-7739-449C-AD43-8079DEB4C0DCQ35582461-B1D6A279-8EF8-44F8-9E4C-54D64524DDCEQ35632910-40668176-987E-4024-A215-7DB471015859Q35637506-B55312FB-397F-498A-8478-952A89B39C67Q35785174-C9A1BE88-F6B2-4A1F-B61D-77C8C24F9B0DQ35833258-8CF1E326-CA7E-4D99-9407-1994483D27A4Q35917357-258F5B7B-1A27-4908-8B1A-3754CDAC3A05Q35917447-76348AAC-45FC-4840-91CF-ED837107E436Q35917541-2C9FAA64-2642-45FF-B669-877951A72B7EQ35925551-2537FFF3-9467-4EA9-877D-564EAFE7071CQ35988546-47FE64D3-5819-42FA-B828-D1C6F37FA4A0Q36135493-2349B7AA-DC1D-43EB-9845-B03A3019787EQ36304057-6DCAC9EB-2FAF-43EA-A7F2-378CF9648CE2Q36393856-412B19F3-22B8-4FA0-B8AB-087617227964Q36435893-A1513487-9DD4-42BE-8FAB-0A23E47CBCDAQ36447557-184FCE7E-8884-40C7-AC24-5A24A406DEA3
P2860
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@en
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@nl
type
label
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@en
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@nl
prefLabel
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@en
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@nl
P2093
P1433
P1476
Adefovir dipivoxil added to on ...... YMDD mutant hepatitis B virus.
@en
P2093
Alison Moorat
Bernard Willems
Carol L Brosgart
David Mutimer
Eric Bourne
Eugene Schiff
Hie-Won Hann
Mary Woessner
Nancy Leung
Robert Perrillo
P356
10.1053/J.GASTRO.2003.10.050
P407
P577
2004-01-01T00:00:00Z